Glimstin MP 2mg/500mg/15mg Tablet is a combination oral hypoglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation leverages the complementary mechanisms of action of its components to achieve effective glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which improves insulin sensitivity in adipose tissue, muscle, and the liver. The combined use of these agents addresses multiple pathophysiological defects in type 2 diabetes, facilitating better glycemic control than monotherapy. Glimstin MP is typically prescribed when diet, exercise, and monotherapy have not achieved adequate glycemic control. It should be used under medical supervision with regular monitoring of blood glucose levels, renal and hepatic function. Caution is advised in patients with contraindications such as severe renal impairment, hepatic dysfunction, or heart failure. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema.